Your search returned 2 results.

Results
	1.	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. [electronic resource] by Yardley, Denise A Brufsky, Adam Coleman, Robert E Conte, Pierfranco F Cortes, Javier Glück, Stefan Nabholtz, Jean-Mark A O'Shaughnessy, Joyce Beck, Robert M Ko, Amy Renschler, Markus F Barton, Debora Harbeck, Nadia Producer: 20160829 In: Trials vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. [electronic resource] by Yardley, Denise A Brufsky, Adam Coleman, Robert E Conte, Pierfranco F Cortes, Javier Glück, Stefan Nabholtz, Jean-Mark A O'Shaughnessy, Joyce Beck, Robert M Ko, Amy Renschler, Markus F Barton, Debora Harbeck, Nadia Producer: 20160527 In: Trials vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search